Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Brightgene Bio-Medical Technology Co. Ltd. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action in the portfolio. This action is being handled by 1 distinct examiner within 1 distinct art unit. STONEBRAKER, ALYSSA RAE is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action.
With only 1 pending office action, the prosecution workload is highly concentrated. Practitioners should tailor their approach to the specific tendencies of STONEBRAKER, ALYSSA RAE, as this examiner oversees the entire pending pipeline. The focus within 1 distinct art unit suggests that the subject matter is specialized within the Biotechnology & Pharmaceuticals field. Resolving the 1 busiest examiner pending action will require a clear understanding of the examiner's previous actions and the technical standards of the assigned art unit. The alignment of the 1 pending office action with a single examiner in the Biotechnology & Pharmaceuticals sector indicates a streamlined path for this specific application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | STONEBRAKER, ALYSSA RAE | 14d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 14d | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrightgene Bio-Medical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Brightgene Bio-Medical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
